Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2009

View Archived Issues

EC-145 shows promising activity in phase II trial in advanced ovarian cancer patients

Toray's Feron approved in Japan for viremia in chronic hepatitis C infection

Questcor resubmits sNDA to FDA for H.P. Acthar Gel for treatment of infantile spasms

Abbott reports results from third quarter of 2009

AN-2728 5% ointment applied twice daily for 6-8 weeks is beneficial in plaque psoriasis therapy

Anti-IL-17A antibody AIN-457 displays efficacy in phase II trial in plaque psoriasis

Novavax begins clinical trial in healthy adults in Mexico of VLP H1N1 influenza vaccine

Phase II results show anti-BAFF monoclonal antibody LY-2127399 to be active in RA

Letrozole combined with imatinib mesylate in patients with metastatic breast cancer

RADAR study of everolimus in breast cancer patients with bone metastases amended

PLX-FK1 inhibits disease progression in experimental models of autoimmune disorders

Action Pharma commences a new phase II trial for AP-214

FDA approves Fluarix seasonal influenza vaccine for children

FDA approves Micardis to reduce the risk of heart attack, stroke and death

BioSante reports phase III LibiGel safety data

Tasigna meets primary endpoint in pivotal trial in chronic myeloid leukemia patients

Pacira reports results from phase III study of Exparel for pain relief after bunionectomy

Health Canada issues NON regarding Winston Laboratories' NDS for Civanex

Abbott acquires Visiogen and Synchrony intraocular lens technology

Shire to file BLA for Replagal for Fabry disease by year end

First patient enrolled in Genzyme's phase III trial of Genz-112638 in Gaucher disease

Cortex Pharmaceuticals reports on CX-1837 in behavioral cognition models

Preclinical data on the novel NPY Y2 receptor antagonist JNJ-31020028 disclosed at Neuroscience 2009

Merck & Co. claims novel CGRP receptor antagonists for migraine

Novel antithrombotic compounds in early development at sanofi-aventis

GlaxoSmithKline discovers novel FAK inhibitors for use as oncolytic agents

Jennerex obtains EMEA orphan drug status for JX-594